AnalystsInsight

Allison Bratzel (Piper Sandler): Analyst Track Record and Price‑Target Accuracy

How often Allison Bratzel’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 462 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+1 new rating (SRRK)

Key takeaways

  • Allison Bratzel ranks #413 of 1,000 analysts in Exent’s scoring (4.8★).
  • 38.5% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 111 days; 69.5% of calls were up 12 months later.
  • Most‑covered stocks: ABVX, TVTX, AKBA, COGT.
  • Free on Exent: Allison Bratzel’s full record, with ratings 3 days after publication.

Allison Bratzel’s track record at a glance

Allison Bratzel of Piper Sandler ranks #413 of the 1,000 analysts Exent scores, with a 4.8★ rating and a focus on healthcare. Over a 7‑year lookback, 38.5% of Allison’s price targets were reached, 13.9 points below the 52.4% average across all analysts.

MetricAllison BratzelAll analysts
Price‑target hit rate38.5%52.4%
Median days to hit target111 days91 days
Calls up after 12 months69.5%64.0%
Median 12‑month return of calls+23.1%+13.4%
Hit rate, last 2 years34.5%—
Average worst drop after a call−25.5%—
Ratings in the sample462—
Stocks covered25—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetAllison Bratzel
Under 30 days17.7%
30–90 days27.1%
90–180 days22.4%
Over 180 days32.9%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Allison Bratzel covers most

StockRatings in the sample
ABVX35
TVTX27
AKBA25
COGT25
ARDX24
ARGX22
BMRN21
BHVN19

In the past year Allison’s ratings were 84% Buy, 16% Hold and 0% Sell.

Allison Bratzel’s latest ratings

DateStockActionRatingPrice target
Sep 15, 2026SRRKReiterated: BuyBuy$75.00
Sep 8, 2026TYRAReiterated: BuyBuy$56.00
Sep 1, 2026BMRNReiterated: BuyBuy$90.00
Aug 26, 2026BMRNReiterated: BuyBuy$88.00
Aug 19, 2026BMRNReiterated: BuyBuy$88.00
Aug 17, 2026HUMAReiterated: HoldHold$1.00
Aug 17, 2026INCYReiterated: BuyBuy$130.00
Aug 17, 2026RIGLReiterated: HoldHold$49.00
Aug 17, 2026AKBAReiterated: BuyBuy$4.00
Aug 17, 2026BHVNReiterated: BuyBuy$30.00
Aug 17, 2026ARGXReiterated: BuyBuy$1215.00
Aug 17, 2026TVTXReiterated: BuyBuy$68.00
  • Sep 15, 2026
    Stock
    SRRK
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $75.00
  • Sep 8, 2026
    Stock
    TYRA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $56.00
  • Sep 1, 2026
    Stock
    BMRN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $90.00
  • Aug 26, 2026
    Stock
    BMRN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $88.00
  • Aug 19, 2026
    Stock
    BMRN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $88.00
  • Aug 17, 2026
    Stock
    HUMA
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $1.00
  • Aug 17, 2026
    Stock
    INCY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $130.00
  • Aug 17, 2026
    Stock
    RIGL
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $49.00
  • Aug 17, 2026
    Stock
    AKBA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $4.00
  • Aug 17, 2026
    Stock
    BHVN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $30.00
  • Aug 17, 2026
    Stock
    ARGX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $1215.00
  • Aug 17, 2026
    Stock
    TVTX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $68.00

Allison’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Allison Bratzel’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Allison Bratzel ranks #413 of 1,000 with a 4.8★ rating. 38.5% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 69.5% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Allison Bratzel’s success rate is 51.0% by the ranking source and 38.5% by Exent’s price-target hit-rate backtest, with a median of 111 days to reach a target.

Allison Bratzel (Piper Sandler) covers 25 stocks, mostly in healthcare. The most frequently rated are ABVX, TVTX, AKBA, COGT, ARDX.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.